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Background & aims: The aims of this study were to identify whether differences in distribution of adi-
pose tissue and skeletal muscle in obese and non-obese individuals contribute to the magnitude of the
postoperative inﬂammatory response and insulin resistance, with and without preoperative treatment
with carbohydrate drinks.
Methods: Thirty-two adults (16 obese/16 non-obese) undergoing elective major open abdominal surgery
participated in this 2  2 factorial, randomised, double-blind, placebo-controlled study. Participants
received Nutricia preOp® or placebo (800 ml on the night before surgery/400 ml 2e3 h preoperatively)
after stratifying for obesity. Insulin sensitivity was measured using the hyperinsulinaemic-euglycaemic
clamp preoperatively and on the 1st postoperative day. Vastus lateralis, omental and subcutaneous fat
biopsies were taken pre- and postoperatively and analysed after RNA extraction. The primary endpoint
was within subject differences in insulin sensitivity.
Results: Major abdominal surgery was associated with a 42% reduction in insulin sensitivity from
mean(SD) M value of 37.3(11.8) mmol kg1 fat free mass (FFM) to 21.7(7.4) mmol kg1 FFM, but this was
not inﬂuenced by obesity or preoperative carbohydrate treatment. Activation of the triggering receptor
expressed on myeloid cells (TREM1) pathway was seen in response to surgery in omental fat samples. In
postoperative muscle samples, gene expression differences indicated activation of the peroxisome
proliferator-activated receptor (PPAR-a)/retinoid X-receptor (RXR-a) pathway in obese but not in non-
obese participants. There were no signiﬁcant changes in gene expression pathways associated with
carbohydrate treatment.domain containing; BMI, Body mass index; CEBP, CCAAT enhancer binding protein; CIDEA, Cell death inducing DFFA-
tomography; DAVID, database for annotation visualisation and integrated discovery; DXA, dual X-ray absorptiometry;
ity pathway analysis; IR, insulin resistance; IL, interleukin; KEGG, Kyoto encyclopaedia of genes and genomes; MYD88,
muscle ring ﬁnger 1; PACS, picture archiving and communication system; PDK, pyruvate dehydrogenase kinase; PI3K/
; PPAR, peroxisome proliferator activated receptor; SOD1, superoxide dismutase; TAG, triacylglycerol; TNF-a, tumour
63; RXR, retinoid X receptor; VL, vastus lateralis.
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and carbohydrate treatment: A randomisedConclusion: The reduction in insulin sensitivity associated with major abdominal surgery was conﬁrmed
but there were no differences associated with preoperative carbohydrates or obesity.
© 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Table 1
Composition of study drinks.
Constituents (per 100 ml) Unit Nutricia preOp® Placebo
Energy kcal
kJ
50
215
1.6
7
Protein g 0 0.02
Carbohydrate g 12.6 0.04
Maltodextrin g 10 0
Sugars g 2.1 0.04
Fat g 0 Trace
Sodium mg (mmol) 50 (2.2) 20 (0.9)
Potassium mg (mmol) 122 (3.1) Unavailable
Chloride mg (mmol) 6 (0.2) Unavailable
Calcium mg (mmol) 6 (0.1) Unavailable
Phosphorus mg (mmol) 1 (0.0) Unavailable
Magnesium mg (mmol) 1 (0.0) Unavailable
Water g 92 801. Introduction
Major surgery induces inﬂammation and metabolic stress, pro-
cesses which may be exacerbated by pre- and postoperative starva-
tion, leading to postoperative insulin resistance (IR) [1e5]. IR is a state
in which, under hyperinsulinaemic-euglycaemic conditions, glucose
uptake is below the lowest quartile for the population under investi-
gation [6], and obese individualsmay bemore prone to develop IR [5].
As IR is associated with an increase in postoperative complica-
tions [1,2,4,5], measures to attenuate it may be beneﬁcial. Some
studies have suggested that administration of carbohydrate poly-
mer (e.g. maltodextrin) drinks up to 2 h preoperatively may reduce
postoperative IR [7e9]. However, three meta-analyses have not
shown a reduction in complications or overall hospital stay when
patients receiving carbohydrate treatment were compared with
those receiving placebo or no treatment [10e12]. Nevertheless, a
one-day reduction in hospital stay was seen in patients undergoing
major abdominal surgery after carbohydrate treatment [11].
The aims of this study were to identify whether differences in
the distribution and physiology of adipose tissue and skeletal
muscle in obese and non-obese individuals contribute to variation
in the magnitude of the postoperative inﬂammatory response and
IR, with and without preoperative carbohydrate treatment.
2. Methods
2.1. Study design, ethics, trial registration and inclusion and
exclusion criteria
This 2 2 factorial, randomised, double-blind, placebo-controlled
study was set in a university teaching hospital. Adults aged 18e80
years undergoing elective major open abdominal surgery were
enrolled after providing informed written consent. The National
Research Ethics Service approved the study (11/EM/0232),whichwas
registered at www.controlled-trials.com (ISRCTN16597586). Exclu-
sion criteria were pregnancy, >10% weight loss in the preceding 3
months, metabolic and endocrine disorders including diabetes mel-
litus and steroid usage, known gastro-oesophageal reﬂux disease or
hiatus hernia, history of pulmonary aspiration, and suspicion of
alcohol or drug abuse. Participants were classiﬁed as obese (BMI
30 kg m2 or waist circumference 94 cm in men or 80 cm in
women) (n ¼ 16) or non-obese (n ¼ 16).
2.2. Interventions, randomisation and blinding
Central computerised randomisation was performed for par-
ticipants to receive Nutricia preOp® (Nutricia Clinical Care, Trow-
bridge, UK) or placebo (Tovali Sugar Free Whole Lemon Drink
diluted 1:4 with water, Tovali Ltd., Carmarthen, UK) (Table 1) after
stratifying for obesity. The drinks were prepared in identical opa-
que bottles by a person not involved in the research. Investigators
remained blinded until all analyses were completed.
2.3. End points and sample size
The primary endpoint was within subject differences in periop-
erative insulin sensitivity (as measured by the hyperinsulinaemic-et al., Postoperative inﬂamma
controlled study, Clinical Nueuglycaemic clamp [HEC] [13]) among obese, non-obese, carbohy-
drate treated and placebo treated participants. Secondary endpoints
were correlation between body composition and changes in IR,
differences in inﬂammatory cytokine gene expression, and differ-
ences in muscle and fat genes controlling carbohydrate and fat
oxidation and insulin signalling. Complicationswithin30daysof the
operation were recorded according to Clavien-Dindo classiﬁcation
[14].
Based on a previous study [7] and with an estimated standard
deviation of 10% in measurements of insulin sensitivity, 8 partici-
pants were required to detect pair-wise differences of 27% between
the two 2 groups (carbohydrate versus placebo) with a power of
80% at a signiﬁcance level of 0.05. Therefore, 8 participants were
recruited to each of the four arms.
2.4. Experimental methods
Participants had a preoperative screening visit (P1) in the week
before surgery. Height, weight, and hip and waist circumferences
were measured, and dual X-ray absorptiometry (DXA) scan and
HEC performed. Participants were randomised to receive Nutricia
preOp® containing 50 g maltodextrin in 400 ml or placebo and
consumed 800 ml on the evening before and 400 ml 2e3 h before
anaesthesia (Table 1). A second HEC was performed on the ﬁrst
postoperative day (P2) (Table 2).
2.4.1. Hyperinsulinaemic-euglycaemic clamp (HEC) [13].
After an overnight fast, two intravenous cannulae were placed,
one in an antecubital vein for the infusion of insulin (Actrapid, Novo
Nordisk, Denmark) and 10% glucose, and the other retrograde into a
dorsal hand vein which was kept in a hot box for sampling of
arterialised blood. A baseline blood sample for measurement of
fasting blood glucose, and inﬂammatory and hormonal markers
was taken. After a 10-min priming infusion, insulin infusion (1 unit
ml1 0.9% saline) was held constant at 120 mIU m2 min1 for
110 min. Blood glucose concentration was determined every 5 min
using the YSI 2300 Stat Plus (YSI Inc., Yellow Springs, OH). Blood
glucose concentration was clamped at 4.5 mmol l1 by infusion of
variable amounts of glucose. The total body glucose disposal rate
(M-value) was calculated during the ﬁnal 15 min (steady-state) andtion and insulin resistance in relation to body composition, adiposity
trition (2018), https://doi.org/10.1016/j.clnu.2018.01.032
Table 2
Time points for blood sampling.
P1 S1 S2 P2
Before surgery (at commencement
of preoperative clamp)
Day of surgery, before knife
to skin
Day of surgery, after closure of the
abdomen
Post-operative day 1 (at commencement
of postoperative clamp)
N. Tewari et al. / Clinical Nutrition xxx (2018) 1e9 3was used as a measure of insulin sensitivity [13]. Insulin concen-
trations were measured during the clamp to allow calculation of
M/I. (Supplementary Digital Content Fig. 1).2.4.2. Body composition analysis
One CT image slice for each participant at the third lumbar
vertebra level was selected and the images were analysed using
SliceOmatic V4.2 software (Tomovision, Montreal, Canada) to
quantify fat free mass (FFM), fat mass (FM), skeletal muscle index
(SMI) and myosteatosis (Supplemental Digital Content e
Experimental) [15e20].2.4.3. Collection and analysis of blood samples
The concentrations of tumour necrosis factor-a (TNFa),
interleukin-6 (IL-6), C-reactive protein (CRP), triacylglycerol (TAG),
blood glucose, plasma cortisol, serum insulin, serum non-esteriﬁed
fatty acids (NEFA) and free fatty acids (FFA) were measured at four
time points (Table 2). Assays are described in the Supplemental
Digital Content e Experimental. The TNF assay was not highly
sensitive, with detection limit of 1 pg ml1.2.4.4. Skeletal muscle and subcutaneous adipose tissue biopsies
Vastus lateralis (VL) muscle biopsies were obtained using a
Weil-Blakesley forceps (medizintechnik, Stuttgart, Germany).
Subcutaneous adipose tissue and omental tissue were also
collected. The samples were snap frozen in liquid nitrogen and
stored at 80 C.2.4.5. RNA extraction
Biopsy samples were defrosted and total RNAwas isolated using
Tri reagent according to the manufacturer's instructions. The RNA
pellet was air-dried for 10 min and then resuspended in 50 mL of
RNase free water, and cDNA was prepared and quantiﬁed
(Supplemental Digital Content e Experimental).2.4.6. TaqMan low density gene array analysis
A custom TaqMan® Array Micro Fluidic Card was designed for
each tissue for gene array analysis (Supplemental Digital Content e
Experimental and Supplemental Digital Content Tables 1 and 2).2.5. Statistical analyses
Statistical analysis was performed with SPSS® for Windows™
v22 software (IBM, Armonk, NY) and GraphPad Prism v6.04
(GraphPad Software Inc., La Jolla, CA). Data are presented as mean
(SE or SD) or median (IQR). The paired and independent samples t-
tests were used for parametric paired and unpaired data, respec-
tively. The Wilcoxon signed rank and ManneWhitney U tests were
used for non-parametric paired and unpaired data, respectively.
The Chi square test was used for categorical data.
Comparisons between the study time points for parametric and
non-parametric data were made using the repeated measures
ANOVA or the KruskaleWallis tests, respectively. Two-tailed p
values, with Welch's correction, are reported and differences were
considered signiﬁcant at p < 0.05.Please cite this article in press as: Tewari N, et al., Postoperative inﬂamma
and carbohydrate treatment: A randomised controlled study, Clinical Nu3. Results
The demographics of the 32 participants (Fig. 1) are shown in
Table 3 and surgical procedures are listed in Supplemental Digital
Content Table 3.
3.1. Hyperinsulinaemic-euglycaemic clamps
There was a 42% decrease (p < 0.001) in insulin sensitivity
(Table 4) from M value (mean (SD) of 37.3 (11.8) mmol kg1 FFM to
21.7 (7.4) mmol kg1 FFM, in both obese and non-obese subjects
between the preoperative visit and the ﬁrst postoperative day.
However, there was no difference in the magnitude of change in
insulin sensitivity between obese and non-obese participants or in
those who received and did not receive carbohydrate drinks
(Table 4). Plasma insulin concentrations were measured and sum-
marised in Supplemental Digital Content Fig. 1. As the magnitude of
change in insulin sensitivity was equivalent when comparing M
values pre- and postoperatively or M/I, M values were used for all
analyses.
3.2. Body composition and insulin sensitivity
Therewas some correlation betweenDXA and CT (Supplemental
Digital Content Table 4) for both fat mass (r2¼ 0.486, p < 0.001) and
fat free mass (r2 ¼ 0.658, p < 0.001). There was no correlation be-
tween the presence of sarcopenia and preoperative (r2 ¼ 0.233,
p ¼ 0.594) or postoperative (r2 ¼ 0.318, p ¼ 0.120) IR. Myosteatosis
was present in 29.6% participants who had preoperative CT scans.
Although there was no correlation between the presence of myo-
steatosis and sarcopenia (p ¼ 0.152), there was signiﬁcant corre-
lation between presence of myosteatosis and postoperative IR
(r2 ¼ 0.746, p ¼ 0.012).
3.3. Complications
There was no signiﬁcant difference in 30-day postoperative
complications between obese and non-obese patents and those
receiving carbohydrate treatment or placebo, when graded ac-
cording to the ClavieneDindo classiﬁcation [14]. Of the 16 obese
patients, 9 had no complications, 3 had Grade I and 4 Grade II
complications. Of the 16 non-obese patients, 10 had no complica-
tions, 3 Grade I, 2 Grade II and 1 Grade IIIb complications (p¼ 0.633,
Chi-square test). Of the 16 patients who received preoperative
carbohydrates, 13 had no complications, 2 Grade I, and 1 Grade II
complications. Of the 16 patients receiving placebo, 6 had no
complications, 4 Grade I, 5 Grade II and 1 Grade IIIb complications
(p ¼ 0.075, Chi-square test). There was no 30-day or in-hospital
mortality.
3.4. Metabolic data
Concentrations of FFA, TAG, Cortisol and cytokines are shown in
Fig. 2. There was a signiﬁcant increase in IL-6 concentration from
the preoperative time point to the end of surgery (p < 0.0001) and
there was a signiﬁcant increase in CRP between the end of surgery
and the ﬁrst postoperative day (p < 0.001). There was no signiﬁcanttion and insulin resistance in relation to body composition, adiposity
trition (2018), https://doi.org/10.1016/j.clnu.2018.01.032
Fig. 1. CONSORT ﬂow diagram.
N. Tewari et al. / Clinical Nutrition xxx (2018) 1e94difference between obese and non-obese participants in IL-6
(p ¼ 0.203), CRP (p ¼ 0.645), FFA (p ¼ 0.446), cortisol (p ¼ 0.322)
or TNFa (p ¼ 0.101) concentrations (data in ﬁgure e combined
placebo and carbohydrate treated data as there were no differences
between groups).3.5. Gene expression analysis of muscle and fat biopsies
Taqman low density arrayswere designed to contain assays for a
selection of genes involved in carbohydrate and lipid metabolism,
insulin signalling, muscle atrophy and inﬂammatory pathways.3.5.1. Effects of surgery
Omental fat sample gene expression results indicated an
elevation of inﬂammatory pathway genes in response to surgery.
Database for annotation visualisation and integrated discovery
(DAVID) analysis of omental fat data revealed that the top two
enriched Kyoto encyclopaedia of genes and genomes (KEGG)
pathways highlighted were ‘regulation of cytokine production’
(NLRP3, IRAK3, IL1B, IL18, C3, HIF1A, CASP1, TGFB1, ADIPOQ,
MYD88, IL6, PPARG, IL10, TNF, SOD1, CIDEA; p ¼ 9.1  1016) and
‘positive regulation of cytokine production’ (IRAK3, CEBPB, C3,
ADIPOQ, PPARG, IL10, CIDEA; p ¼ 2.1  1010). Activation of the
triggering receptor expressed on myeloid cells (TREM1) pathway,
which ampliﬁes inﬂammatory signalling, was also seen in response
to surgery in omental fat samples (Supplemental Digital Content
Fig. 2). This was demonstrated by a positive Z score (2.646,
p < 0.0001) on ingenuity pathway analysis (IPA). The Z score in IPA
infers the activation state of predicted transcriptional regulators
based on experimentally observed gene expression or transcription
events.
In VL, there were surprisingly few changes in gene expression in
response to surgery, however there was a signiﬁcant decrease in
expression of tripartite motif containing 63 (TRIM 63) gene, alsoPlease cite this article in press as: Tewari N, et al., Postoperative inﬂamma
and carbohydrate treatment: A randomised controlled study, Clinical Nuknown as muscle ring ﬁnger 1 (MURF-1) between pre- and post-
operative samples.
3.5.2. Differences between obese and non-obese participants
In postoperative VL samples, gene expression differences indi-
cated increased activation of the peroxisome proliferator-activated
receptor (PPAR-a)/retinoid X-receptor (RXR-a) pathway in obese
compared with non-obese participants (Supplemental Digital
Content Fig. 3). This was demonstrated by a negative Z score
(1.000, p < 0.0001) on IPA. This was conﬁrmed on DAVID analysis
which highlighted ‘fatty acid metabolism’ (p ¼ 2.8  1014) and
PPAR signalling pathway (p ¼ 6.0  1013) as the top two enriched
pathways from KEGG.
3.5.3. Effects of carbohydrate loading
In VL samples, there were no signiﬁcant differences in post-
operative gene expression between carbohydrate and placebo
treated participants. In obese participants, in VL samples, no dif-
ferences were seen postoperatively between carbohydrate and
placebo treatments. There were individual gene expression
changes in non-obese carbohydrate loaded participants compared
with those receiving placebo but these did not indicate major
changes in any particular metabolic or signalling pathway. Post-
operatively, in omental fat, there were no differences between
samples from carbohydrate-treated or placebo-treated partici-
pants. In abdominal fat, there was little inﬂuence of carbohydrate
treatment or obesity on perioperative changes in gene expression.
In particular, carbohydrate loading had no discernible effect in any
tissue upon expression of genes involved in carbohydrate meta-
bolism or insulin signalling.
4. Discussion
This study has shown that although insulin sensitivity was
decreased after major surgery in both obese and non-obesetion and insulin resistance in relation to body composition, adiposity
trition (2018), https://doi.org/10.1016/j.clnu.2018.01.032
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and carbohydrate treatment: A randomised controlled study, Clinical Nusubjects, preoperative carbohydrate treatment or obesity did not
have an impact on the magnitude of change. In addition, gene
expression analyses suggested that both lipid and carbohydrate
metabolism pathways were activated by surgery, but not altered by
carbohydrate treatment. Although previous reports suggest
increased risk of morbidity in obese patients undergoing surgery
[15], in the present study, there were no differences in post-
operative complications between obese and non-obese partici-
pants nor between carbohydrate and placebo treated participants.
The ClavieneDindo classiﬁcation [14] is a standard and accepted
means of reporting postoperative complications. Although this
study was not powered to detect a difference in complication rate,
previous meta-analyses have not shown a difference in post-
operative complications between carbohydrate and placebo treated
individuals [11,12].
It has been suggested that preoperative carbohydrate treatment
reduces themagnitude of postoperative IR [7e9]. In a small study in
colorectal surgery (n ¼ 14), administration of 100 g oral carbohy-
drate on the night before and 50 g on the morning of surgery was
associated with less reduction in whole body glucose disposal
compared with the fasted group [7]. There have been two other
small studies utilising the HEC which have demonstrated a reduc-
tion in IR in preoperative carbohydrate treated patients compared
with placebo [8,9]. In a recent animal study, postoperative whole
body glucose disposal rate was higher after carbohydrate treatment
than fasting and this correlated negatively with muscle PDK4
protein expression [16]. The same study group demonstrated, in
pigs, that a single dose of carbohydrate preoperatively was sufﬁ-
cient to reduce postoperative IR, as measured by the HEC [17].
However, a recent multiple-treatments meta-analysis on 62 par-
ticipants studied using HEC showed no signiﬁcant difference in any
of the comparisons (between carbohydrate treatment and fasting,
water or placebo) [12].
Serum markers of the inﬂammatory response increased with
surgery. There was no signiﬁcant change in TNF-a but there was a
signiﬁcant change in IL-6. This is in keeping with previous studies
of major surgery and suggests that IL-6 may be the main driver of
the postoperative response [18] while TNF-a is involved in the in-
ﬂammatory response to sepsis [19].
Gene expression analysis of abdominal fat, VL and omental fat
before and after surgery indicated that adaptive changes in gene
expression did occur in response to surgery, but not in response to
carbohydrate treatment. Changes in the PPARa/RXRa pathway
were demonstrated in postoperative VL samples of obese compared
with non-obese participants. PPARa is a master transcriptional
regulator of fatty acid oxidation [19e22] and the PPARa pathway is
induced during fasting. In mouse models, PPARa agonists reduced
adiposity, decreasedmuscle and hepatic steatosis and consequently
improved insulin sensitivity [23e26]. Activation of this pathway in
the present study may be reﬂective, in part, of preoperative fasting
but this does not account for the increased activation in obese
compared with non-obese participants. There are some parallels
with the Randle hypothesis which suggested in rats that substrate
competition between NEFAs and glucose served as an energy
source for muscle [27], resulting in a relative increase in fat
oxidation compared with carbohydrate metabolism in response to
increased NEFAs.
Muscle atrophy has been observed in response to protein energy
malnutrition and fasting, but is also a feature of immobility, dia-
betes, cancer cachexia and sepsis [28]. An increased expression of
TRIM63 gene (MURF-1) has been observed in models of muscle
wasting, including fasting [29]. However, in a study examining
skeletal muscle of volunteers subjected to a short-term fast, there
was no signiﬁcant change in MURF-1 expression. Therefore, the
changes observed in the present study in TRIM63 and related genestion and insulin resistance in relation to body composition, adiposity
trition (2018), https://doi.org/10.1016/j.clnu.2018.01.032
Fig. 2. Perioperative changes in concentrations of interleukin 6 (IL-6), tumour necrosis factor a (TNF-a), cortisol, C-reactive protein (CRP), triacylglycerol (TAG) and free fatty acid
(FFA). P1 ¼ preoperative, S1 ¼ start of surgery, S2 ¼ end of surgery and P2 ¼ ﬁrst postoperative day. **p < 0.05, ***p < 0.001.
Table 4
M values at visit 1 and 2 (mean (SD)) and postoperative reduction insulin sensitivity in obese vs. non-obese participants and those receiving carbohydrate vs. placebo. There
was no inﬂuence of gender, age, cancer status or length of surgical procedure on the change in insulin sensitivity (data not shown). The reduction in insulin sensitivity between
the preoperative (100%) and postoperative M values was statistically signiﬁcant (p < 0.001) for all groups.
Groups All Obese Non-obese Difference between groups
All (n ¼ 32) (n ¼ 16) (n ¼ 16) p ¼ 0.38
Preoperative M value mean (SD) mmol kg1 37.3 (11.8) 41.6 (11.7) 33.1 (10.7)
Postoperative M value mean (SD) mmol kg1 21.7 (7.4) 24.5 (7.6) 19.2 (7.4)
Reduction in insulin sensitivity 42% 41% 42%
Carbohydrate treated (n ¼ 16) (n ¼ 8) (n ¼ 8) p ¼ 0.19
Preoperative M value mean (SD) mmol kg1 36.2 (11.4) 32.5 (8.8) 40.3 (13.0)
Postoperative M value mean (SD) mmol kg1 19.5 (6.1) 18.2 (6.3) 21 (6.0)
Reduction in insulin sensitivity 46% 44% 48%
Placebo (n ¼ 16) (n ¼ 8) (n ¼ 8) p ¼ 0.06
Preoperative M value mean (SD) mmol kg1 38.5 (12.6) 33.8 (13.3) 43.1 (10.8)
Postoperative M value mean (SD) mmol kg1 22 (8.5) 17.6 (8.4) 26.7 (8.9)
Reduction in insulin sensitivity 43% 48% 38%
Difference between groups p ¼ 0.67 p ¼ 0.23 p ¼ 0.23
N. Tewari et al. / Clinical Nutrition xxx (2018) 1e96
Please cite this article in press as: Tewari N, et al., Postoperative inﬂammation and insulin resistance in relation to body composition, adiposity
and carbohydrate treatment: A randomised controlled study, Clinical Nutrition (2018), https://doi.org/10.1016/j.clnu.2018.01.032
Fig. 3. In surgical trauma, increased production and release of inﬂammatory cytokines leads to NFkB-mediated inhibition of insulin signalling and subsequent decrease in glucose
uptake and utilization. Increased glucocorticoid release on the other hand will increase expression of PPARa and lead to an increase in beta oxidation of fatty acids. In concert with
these changes in metabolic substrate utilization, the expression of Murf1 and Atrogin1 are decreased post operatively by and as yet unknown mechanism. The net result of these
changes re glucose and protein being spared in exchange for increased utilization of fatty acids in the short-term response to surgical trauma. (AKT ¼ protein kinase B,
GRa ¼ glucocorticoid receptor a, Murf1 ¼ muscle RING-ﬁnger protein-1, NFkB ¼ nuclear factor kappa-light-chain-enhancer of activated B cells, PI3K ¼ phosphatidylinositide 3-
kinase, PPARa ¼ peroxisome proliferator-activated receptor a).
N. Tewari et al. / Clinical Nutrition xxx (2018) 1e9 7are unlikely to be due to fasting alone [30]. Induction of TRIM63 has
been observed in immobilisation-induced muscle atrophy [30] but
the length of surgery in the present study is unlikely to have been
sufﬁcient to induce atrophy. In this study, TRIM 63 gene expression
was decreased postoperatively in VL samples, which is counterin-
tuitive in the context of the current literature. In addition, FBOX032
(atrogin) expression decreased. Atrogin belongs to the ubiquitin
proteasome pathway, the primary pathway involved in intracel-
lular protein degradation in skeletal muscle [26]. A decrease in
TRIM 63 (MURF 1) and atrogin (FBOX032) would suggest adapta-
tion to counteract myoﬁbril degradation (Fig. 3). Transgenic mice
overexpressing TRIM63 did not present with muscle atrophy but
had hyperinsulinemia and reduced hepatic glycogen stores [31].
The changes demonstrated in the present study have also been
described following stimulation of a catabolic state resulting in
muscle atrophy [32].
The most conspicuous ﬁnding in omental fat was activation of
the TREM1 pathway postoperatively. TREM1 expression has so far
been studied primarily in immune cells and its activation resulted
in increased production of pro-inﬂammatory cytokines such as IL-
1b and TNFa as well as chemokines such as IL-8 and MCP-1. Surface
expression of TREM1 in peripheral blood mononuclear cells was
increased signiﬁcantly in postoperative patients compared with
controls, with an even higher expression observed in septic pa-
tients [33]. In acute pancreatitis, expression of TREM-1 correlated
with disease severity [34]. The activation of the TREM1 pathway in
omental samples postoperatively is likely to represent part of the
inﬂammatory response to surgery.
The present study has some limitations. There was heteroge-
neity in terms of participant age and comorbidities. Every effort
was made to ensure that procedures were comparable, in terms of
length of procedure and blood loss, but in this relatively small
patient group, the variability may have affected results. A standard
technique of calculation of insulin dose using body surface area
was used [13] but this may have overestimated the insulin dose
required per unit of lean mass in obese individuals and, thereby,Please cite this article in press as: Tewari N, et al., Postoperative inﬂamma
and carbohydrate treatment: A randomised controlled study, Clinical Nuresulted in greater glucose disposal. However, when the M value
was corrected for the circulating insulin concentration during
the clamp, there remained no signiﬁcant difference in the change
in perioperative insulin sensitivity between lean and obese
individuals.
The HEC was performed with an intentionally high insulin dose
to suppress hepatic (and possibly renal) gluconeogenesis and to
overcome at least the expected insulin resistance of the obese
group. Hence, our ﬁndings are not directly comparable with those
in the literature using HEC to evaluate insulin sensitivity changes in
surgical patients, but the same protocol was used pre- and post-
operatively. Thus, the results demonstrate that even at these high
rates of insulin infusion, postoperative IR is substantial. The glucose
infused during the HEC to maintain euglycaemia is a measure of
insulin sensitivity/resistance. In starvation or after trauma/surgery
the insulin resistance is reﬂected by a lower rate of glucose infusion
at a ﬁxed insulin infusion. In both conditions, the endocrine and
cytokine responses will stimulate hepatic gluconeogenesis, but the
insulin infusion rate selected for this study should suppress most if
not all of this increased glucose production. This can only be
absolutely conﬁrmed with tracer infusions, which were not per-
formed in this study. Thus, it is possible there was still some re-
sidual endogenous glucose production, but this will not have offset
the almost 50% reduction in glucose infusion rate in the post-
surgical state.
In conclusion, the evidence for recommendation of preoperative
carbohydrate treatment care is not as strong as believed previously
[35] and further large scale well-designed randomised controlled
studies looking at patient-centred outcomes are needed before a
ﬁrm conclusion can be made on its efﬁcacy. It is also possible that
due to the overall improvement in perioperative care including
avoidance of prolonged preoperative starvation and introduction of
other measures to reduce perioperative inﬂammation, themarginal
gains noted in initial studies on carbohydrate treatment may not be
apparent in a multimodal pathway designed to decrease the post-
operative response to metabolic stress.tion and insulin resistance in relation to body composition, adiposity
trition (2018), https://doi.org/10.1016/j.clnu.2018.01.032
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